FDA Approves Trial To Treat Opioid Addiction With CBD
Nantheia ATL5 is an oral product with 100mg of CBD per soft gel capsule
The U.S. Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for a clinical trial to evaluate CBD as an adjunctive method to treat opioid use disorder.
Biotech pharma company Ananda Scientific Inc. announced in January 2022 the FDA’s approval for the clinical trial evaluating Nantheia ATL5, an investigational drug using CBD as an adjunctive treatment for opioid use disorder. The study will be conducted at the University of California, Los Angeles (UCLA).
Nantheia ATL5 is an oral product with 100mg of CBD per soft gel capsule utilizing Liquid Structure technology, licensed from the Israeli pharmaceutical company Lyotropic Delivery Systems, which enhances the effectiveness and stability of CBD.
Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure technology would enhance the effectiveness and stability of CBD.
To Read The Rest Of This Article On Forbes, Click Here
